Cited 17 times in
Long Pentraxin 3 as a Predictive Marker of Mortality in Severe Septic Patients Who Received Successful Early Goal-Directed Therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 구남수 | - |
dc.contributor.author | 김준명 | - |
dc.contributor.author | 송영구 | - |
dc.contributor.author | 이경화 | - |
dc.contributor.author | 전용덕 | - |
dc.contributor.author | 최준용 | - |
dc.contributor.author | 한상훈 | - |
dc.contributor.author | 김정호 | - |
dc.date.accessioned | 2017-11-02T08:09:36Z | - |
dc.date.available | 2017-11-02T08:09:36Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 0513-5796 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/154146 | - |
dc.description.abstract | PURPOSE: Pentraxin 3 (PTX3) has been suggested to be a prognostic marker of mortality in severe sepsis. Currently, there are limited data on biomarkers including PTX3 that can be used to predict mortality in severe sepsis patients who have undergone successful initial resuscitation through early goal-directed therapy (EGDT). MATERIALS AND METHODS: A prospective cohort study was conducted among 83 severe sepsis patients with fulfillment of all EGDT components and the achievement of final goal. Plasma PTX3 levels were measured by sandwich ELISA on hospital day (HD) 0, 3, and 7. The data for procalcitonin, C-reactive protein and delta neutrophil index were collected by electric medical record. The primary outcome was 28-day all-cause mortality. RESULTS: 28-day all-cause mortality was 19.3% and the median (interquartile range) APHCH II score of total patients was 16 (13-19). The non-survivors (n=16) had significantly higher PTX3 level at HD 0 [201.4 (56.9-268.6) ng/mL vs. 36.5 (13.7-145.3) ng/mL, p=0.008]. PTX3 had largest AUC(ROC) value for the prediction of mortality among PTX3, procalcitonin, delta neutrophil index, CRP and APACHE II/SOFA sore at HD 0 [0.819, 95% confidence interval (CI) 0.677-0.961, p=0.008]. The most valid cut-off level of PTX3 at HD 0 was 140.28 ng/mL (sensitivity 66.7%, specificity 73.8%). The PTX3 and procalcitonin at HD 0 showed strong correlation (r=0.675, p<0.001). However, PTX3 at HD 0 was the only independent predictive marker in Cox's proportional hazards model (≥140 ng/mL; hazard rate 7.16, 95% CI 2.46-15.85, p=0.001). CONCLUSION: PTX3 at HD 0 could be a powerful predictive biomarker of 28-day all-cause mortality in severe septic patients who have undergone successful EGDT. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Yonsei University | - |
dc.relation.isPartOf | YONSEI MEDICAL JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | APACHE | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Biomarkers/blood | - |
dc.subject.MESH | C-Reactive Protein/analysis* | - |
dc.subject.MESH | C-Reactive Protein/metabolism | - |
dc.subject.MESH | Calcitonin/blood | - |
dc.subject.MESH | Cause of Death | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Leukocyte Count | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neutrophils | - |
dc.subject.MESH | Organ Dysfunction Scores | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Proportional Hazards Models | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | ROC Curve | - |
dc.subject.MESH | Reference Standards | - |
dc.subject.MESH | Sensitivity and Specificity | - |
dc.subject.MESH | Sepsis/blood | - |
dc.subject.MESH | Sepsis/mortality* | - |
dc.subject.MESH | Serum Amyloid P-Component/analysis* | - |
dc.subject.MESH | Time Factors | - |
dc.title | Long Pentraxin 3 as a Predictive Marker of Mortality in Severe Septic Patients Who Received Successful Early Goal-Directed Therapy | - |
dc.type | Article | - |
dc.publisher.location | Korea (South) | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Sun Bean Kim | - |
dc.contributor.googleauthor | Kyoung Hwa Lee | - |
dc.contributor.googleauthor | Ji Un Lee | - |
dc.contributor.googleauthor | Hea Won Ann | - |
dc.contributor.googleauthor | Jin Young Ahn | - |
dc.contributor.googleauthor | Yong Duk Jeon | - |
dc.contributor.googleauthor | Jung Ho Kim | - |
dc.contributor.googleauthor | Nam Su Ku | - |
dc.contributor.googleauthor | Sang Hoon Han | - |
dc.contributor.googleauthor | Jun Yong Choi | - |
dc.contributor.googleauthor | Young Goo Song | - |
dc.contributor.googleauthor | June Myung Kim | - |
dc.identifier.doi | 10.3349/ymj.2017.58.2.370 | - |
dc.contributor.localId | A00953 | - |
dc.contributor.localId | A02037 | - |
dc.contributor.localId | A04620 | - |
dc.contributor.localId | A03534 | - |
dc.contributor.localId | A04191 | - |
dc.contributor.localId | A04286 | - |
dc.contributor.localId | A00189 | - |
dc.relation.journalcode | J02813 | - |
dc.identifier.eissn | 1976-2437 | - |
dc.identifier.pmid | 28120568 | - |
dc.subject.keyword | Pentraxin 3 | - |
dc.subject.keyword | early-goal directed therapy | - |
dc.subject.keyword | mortality | - |
dc.subject.keyword | predictive biomarker | - |
dc.subject.keyword | severe sepsis | - |
dc.contributor.alternativeName | Ku, Nam Su | - |
dc.contributor.alternativeName | Kim, June Myung | - |
dc.contributor.alternativeName | Song, Young Goo | - |
dc.contributor.alternativeName | Lee, Kyoung Hwa | - |
dc.contributor.alternativeName | Jeon, Yong Duk | - |
dc.contributor.alternativeName | Choi, Jun Yong | - |
dc.contributor.alternativeName | Han, Sang Hoon | - |
dc.contributor.affiliatedAuthor | Kim, June Myung | - |
dc.contributor.affiliatedAuthor | Song, Young Goo | - |
dc.contributor.affiliatedAuthor | Lee, Kyoung Hwa | - |
dc.contributor.affiliatedAuthor | Jeon, Yong Duk | - |
dc.contributor.affiliatedAuthor | Choi, Jun Yong | - |
dc.contributor.affiliatedAuthor | Han, Sang Hoon | - |
dc.contributor.affiliatedAuthor | Ku, Nam Su | - |
dc.citation.title | Yonsei Medical Journal | - |
dc.citation.volume | 58 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 370 | - |
dc.citation.endPage | 379 | - |
dc.identifier.bibliographicCitation | YONSEI MEDICAL JOURNAL, Vol.58(2) : 370-379, 2017 | - |
dc.date.modified | 2017-11-01 | - |
dc.identifier.rimsid | 42108 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.